RSRichard Scott Swain

Richard Scott Swain

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Richard Scott Swain has a total of 131 co-authors. Here are the top co-authors by number of shared publications:

  • Andrew D. Mosholder

    U.S. Food and Drug Administration Center for Drug Evaluation and Research, Division of Epidemiology I, Silver Spring MD, United States

    3 shared publications
  • Andrew D. Mosholder

    Formerly at U.S. Food and Drug Administration, Silver Spring, Maryland, USA

    2 shared publications
  • Andrew Petrone

    Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA

    2 shared publications
  • Dinci Pennap

    Formerly Division of Epidemiology U.S. Food and Drug Administration, Center for Drug Evaluation and Research Silver Spring Maryland USA

    2 shared publications
  • Jeffrey A. Kelman

    Centers for Medicare and Medicaid Services Washington District of Columbia USA

    2 shared publications
  • Sandia Akhtar

    Acumen LLC Burlingame California USA

    2 shared publications

Latest Publications

  • Open Access

    A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano study

    by Richard Scott Swain, Andrew Klink, Parisa Asgarisabet, Kristin M Zimmerman Savill, Bindu Kalesan, Alexandrina Balanean, Harlen Hays, Jill Kaufman, Lindsay McAllister, Courtney Omary, et al.

    Aim: In oncology trials, blinded independent central review (BICR) is the standard for treatment response classification. Real-world data methodologies that align with BICR may reduce misclassification in real-world evidence (RWE) studies and enhance reproducibility, increasing value of RWE. We aimed to develop and validate a novel real-world data-based methodology – real-world Lugano (rwLugano) – for assessing lymphoma response to align with clinical trials. Materials & methods: We conducted a retrospective, multisite chart abstraction study using Cardinal Health Practice Research Network (PRN) sites to identify adults with diffuse large B-cell lymphoma initiating first-line (1L) therapy from 1 January 2015, through 31 December 2022, in US community oncology. Sites collected patient characteristics and PET/CT scans at baseline and first response. Two radiologists independently classified responses; a medical oncologist adjudicated discordances. Results: We compared initial treatment responses using three methods: physician-charted from electronic health records, rwLugano-derived per Lugano 2014 and BICR-adjudicated per Lugano 2014. Agreement was assessed via percentage concordance, kappa (κ), and multivariable generalized linear mixed modeling for assigning complete response (CR). Among 178 patients, CR rates were 63.5% (physician-charted), 81.5% (rwLugano) and 83.1% (BICR). Compared with BICR, rwLugano showed higher agreement (87.9%, κ = 0.52) than physician-charted (77.0%, κ = 0.40). The generalized linear mixed modeling analyses identified clinical factors associated with concordance: for physician charted assessments, greater numbers of extranodal sites increased agreement with BICR (OR 1.92), while MYC mutation (OR 0.38) and anemia (OR 0.37) reduced agreement. For rwLugano, nonprivate insurance was associated with higher agreement (odds ratio [OR]: 4.40), whereas MYC mutation reduced agreement (OR: 0.26). Conclusion: rwLugano improves real-world lymphoma response classification, aligning with BICR and supporting more accurate, reproducible RWE for clinical and regulatory decision-making. Using methods BICR and rwLugano may provide opportunities to minimize outcome misclassification and improve comparability of clinical trial and clinical practice approaches.


  • Comparing the Centers for Medicare and Medicaid Services (CMS) enrollment data death dates to the National Death Index (NDI)

    by Dinci Pennap, Richard S. Swain, Sandia Akhtar, Jiemin Liao, Yuqin Wei, Jiaqi Li, Michael Wernecke, Thomas E. MaCurdy, Jeffrey A. Kelman, Andrew D. Mosholder, et al.

    Purpose: In the United States, the National Death Index (NDI) is the most complete source of death information, while epidemiologic studies with mortality outcomes often rely on U.S. Medicare data for outcome ascertainment. The purpose of this study was to assess the agreement of death information between the Centers for Medicare & Medicaid Services (CMS) Medicare enrolment data and NDI.Methods: Using Medicare and NDI data from 1999 through 2016, we identified Medicare beneficiaries who were reported dead in the CMS Medicare enrolment database (EDB) and Common Medicare Environment (CME), linked these beneficiaries to the NDI using CMS Health Insurance Claim number, and compared death dates between the two data sources. To assess agreement between our data sources, we calculated kappa scores; where a kappa of 1 indicates perfect agreement and a kappa of 0 indicates agreement equivalent to chance. We also examined CMS to NDI linkage and death date matching for stability over time.Results: Of the 36 785 640, Medicare beneficiaries reported dead in CMS enrollment data from 1999 to 2016, 97.5% were linked to the NDI. A kappa score of 0.98 showed a near perfect agreement between NDI and CMS reported deaths. The percentage of linked cases exactly matching on death dates increased from 94.8% in 1999 to 99.4% in 2016.Conclusions: Our findings suggest strong concordance between death dates as recorded by CMS enrollment data and the NDI in the entire Medicare population.


  • Risk of hospitalized depression and intentional self-harm with brand and authorized generic sertraline

    by Dinci D. Pennap, Richard S. Swain, Emily C. Welch, Justin Bohn, Jennifer G. Lyons, Sarah Dutcher, Andrew D. Mosholder


  • Second cancers in adults with acute promyelocytic leukemia treated with or without arsenic trioxide: a SEER-medicare analysis

    by Kelly J. Norsworthy, Armen Avagyan, Steven T. Bird, Yuchen Li, Sandia Akhtar, Jiemin Liao, Michael Wernecke, Albert B. Deisseroth, Meredith Chuk, Thomas E. MaCurdy, et al.


  • Challenges of Suicide Outcomes Ascertainment in Administrative Claims Databases

    by Dinci D. Pennap, Andrew D. Mosholder, Richard S. Swain

    To the Editor A recent article by Brent and colleagues concluded that “Children of parents who use prescription opioids are at increased risk for suicide attemp


  • Use of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis

    by Christian Hampp, Richard S. Swain, Casie Horgan, Elizabeth Dee, Yandong Qiang, Sarah K. Dutcher, Andrew Petrone, Rong Chen Tilney, Judith C. Maro, Catherine A. Panozzo

    OBJECTIVE: To estimate real-world off-label use of sodium–glucose cotransporter 2 (SGLT2) inhibitors in patients with type 1 diabetes, estimate rates of diabetic ketoacidosis (DKA), and compare them with DKA rates observed in sotagliflozin clinical trials. RESEARCH DESIGN AND METHODS: We identified initiators of SGLT2 inhibitors in the Sentinel System from March 2013 to June 2018, determined the prevalence of type 1 diabetes using a narrow and a broad definition, and measured rates of DKA using administrative claims data. Standardized incidence ratios (SIRs) were calculated using age- and sex-specific follow-up time in Sentinel and age- and sex-specific DKA rates from sotagliflozin trials 309, 310, and 312. RESULTS: Among 475,527 initiators of SGLT2 inhibitors, 0.50% and 0.92% met narrow and broad criteria for type 1 diabetes, respectively. Rates of DKA in the narrow and broad groups were 7.1/100 person-years and 4.3/100 person-years, respectively. Among patients who met narrow criteria for type 1 diabetes, rates of DKA were highest for patients aged 25–44 years, especially females aged 25–44 years (19.7/100 person-years). More DKA events were observed during off-label use of SGLT2 inhibitors in Sentinel than would be expected based on sotagliflozin clinical trials (SIR = 1.83; 95% CI 1.45–2.28). CONCLUSIONS: Real-world off-label use of SGLT2 inhibitors among patients with type 1 diabetes accounted for a small proportion of overall SGLT2 inhibitor use. However, the risk for DKA during off-label use was notable, especially among young, female patients. Although real-word rates of DKA exceeded the expectation based on clinical trials, results should be interpreted with caution due to differences in study methods, patient samples, and study drugs.


  • A comparison of opioid‐involved fatalities captured in the National Poison Data System to data derived from US death certificate literal text

    by Celeste A. Mallama, James P. Trinidad, Richard S. Swain, Yueqin Zhao, Corinne Woods, Jana K. McAninch

    Purpose: The purpose of the study is to describe and compare the number and characteristics of opioid‐involved fatal cases captured in the National Poison Data System (NPDS) and in US death certificates.Methods: NPDS, which collects data on all calls to US poison control centers, and Drug‐Involved Mortality (DIM), which combines information from literal text of US death certificates and National Vital Statistics Systems, were queried for opioid‐involved fatal cases from 2010 to 2015. Characteristics of the two case series were compared.Results: DIM contained 154 016 opioid‐involved overdose deaths, and NPDS contained 2524 fatal opioid exposures, a ratio of 61:1. The number of opioid deaths remained stable in NPDS but increased in DIM over the 6‐year period. On average, deaths involving opioids with higher mean dosage strength (in morphine milligram equivalents) per unit among dispensed prescriptions were more likely to be captured in DIM relative to NPDS, as compared with those with a lower mean dosage strength per unit. The increase in fentanyl‐related deaths seen in DIM since 2013 was not observed in NPDS.Conclusions: NPDS is a valuable drug safety surveillance resource due to its timeliness and drug specificity. However, it captures only a small fraction of opioid‐involved fatal poisonings, and comparisons with data derived from death certificate literal text indicate that caution is warranted in making inferences about opioid‐involved fatality trends over time or comparisons across opioids.


  • Open Access

    A systematic review of validated suicide outcome classification in observational studies

    by Richard S Swain, Lockwood G Taylor, Elisa R Braver, Wei Liu, Simone P Pinheiro, Andrew D Mosholder

    Background: Suicidal outcomes, including ideation, attempt, and completed suicide, are an important drug safety issue, though few epidemiological studies address the accuracy of suicidal outcome ascertainment. Our primary objective was to evaluate validated methods for suicidal outcome classification in electronic health care database studies.Methods: We performed a systematic review of PubMed and EMBASE to identify studies that validated methods for suicidal outcome classification published 1 January 1990 to 15 March 2016. Abstracts and full texts were screened by two reviewers using prespecified criteria. Sensitivity, specificity, and predictive value for suicidal outcomes were extracted by two reviewers. Methods followed PRISMA-P guidelines, PROSPERO Protocol: 2016: CRD42016042794.Results: We identified 2202 citations, of which 34 validated the accuracy of measuring suicidal outcomes using International Classification of Diseases (ICD) codes or algorithms, chart review or vital records. ICD E-codes (E950-9) for suicide attempt had 2–19% sensitivity, and 83–100% positive predictive value (PPV). ICD algorithms that included events with ‘uncertain’ intent had 4–70% PPV. The three best-performing algorithms had 74–92% PPV, with improved sensitivity compared with E-codes. Read code algorithms had 14–68% sensitivity and 0–56% PPV. Studies estimated 19–80% sensitivity for chart review, and 41–97% sensitivity and 100% PPV for vital records.Conclusions: Pharmacoepidemiological studies measuring suicidal outcomes often use methodologies with poor sensitivity or predictive value or both, which may result in underestimation of associations between drugs and suicidal behaviour. Studies should validate outcomes or use a previously validated algorithm with high PPV and acceptable sensitivity in an appropriate population and data source.


  • Development and validation of algorithms to identify newly diagnosed type 1 and type 2 diabetes in pediatric population using electronic medical records and claims data

    by Dana Y. Teltsch, Soulmaz Fazeli Farsani, Richard S. Swain, Stefan Kaspers, Samuel Huse, Christina Cristaldi, Beth L. Nordstrom, Kimberly G. Brodovicz

    Purpose: To develop and validate algorithms to classify diabetes type in newly diagnosed pediatric patients with DM.Method: Data from the United States Department of Defense health system were used to identify patients aged 10 to 18 years with incident DM. Two independent sets of 200 children were randomly sampled for algorithm development and validation. Algorithms were developed based on clinical insight, published literature, and quantitative approaches. The actual DM type was ascertained via chart review. Finally, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were evaluated.Results: Among the 400 patients, mean age was 14.2 (±2.5 years), and 50% were female. The best performing algorithms were based on data available in claims. They consisted of several logical expressions based on one predictor or more, which classified patients by use of glucose‐lowering drugs or testing, DM ICD‐9 diagnosis codes, and comorbidities. The best performing T2DM and T1DM algorithms achieved 90% and 98% sensitivity, 95% and 95% specificity, 87% and 98% PPV, and 96% and 96% NPV, respectively.Conclusions: Our results suggest that claims algorithms can accurately identify newly diagnosed T1DM and T2DM pediatric patients, which can facilitate large database studies in children with T1DM and T2DM. However, external validation in other data sources is needed.


  • Diagnostic Algorithms for Cardiovascular Death in Administrative Claims Databases: A Systematic Review

    by Sonal Singh, Hassan Fouayzi, Kathryn Anzuoni, Leah Goldman, Jea Young Min, Marie Griffin, Carlos G. Grijalva, James A. Morrow, Christine C. Whitmore, Charles E. Leonard, et al.

    Valid algorithms for identification of cardiovascular (CV) deaths allow researchers to reliably assess the CV safety of medications, which is of importance to regulatory science, patient safety, and public health.